Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jincao Xiaodu Keli is an investigational Traditional Chinese Medicine (TCM) granule formulation developed by Nanning Duoling Biotechnology for the treatment of advanced hepatocellular carcinoma (HCC). The product is currently being evaluated in a Phase 1 clinical trial in China (CTR20233226) to assess its safety, tolerability, and preliminary efficacy in patients with liver cancer. As a TCM "Xiaodu" (detoxifying) formula, it is designed to address the complex pathology of advanced malignancy through the synergistic effects of its botanical constituents, although its specific molecular mechanism of action remains undisclosed in public clinical registries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jincao Xiaodu Keli.